AstraZeneca PLC (AZN) - צמיחת רווחי EPS רבעונית
AstraZeneca PLC (AZN) is a leading biopharmaceutical behemoth providing treatments to patients and government agencies within the cardiology and oncology segments. The quarterly EPS growth trend captures this momentum, with 23.00 reflecting the latest level of the metric. The synergy of developments for rare pathologies creates a unique ecosystem, while the current portfolio of life-saving medicines guarantees sustainable demand and business growth.
%20%D7%A9%D7%99%D7%A0%D7%95%D7%99%20%D7%91%D7%A8%D7%95%D7%95%D7%97%20%D7%A0%D7%A7%D7%99%20%D7%9C%D7%9E%D7%A0%D7%99%D7%94%20%D7%9E%D7%A9%D7%A0%D7%94%20%D7%9C%D7%A9%D7%A0%D7%94%20%D7%91%D7%A9%D7%A0%D7%99%D7%9D%20%D7%A2%D7%A9%D7%A8%20%D7%94%D7%97%D7%95%D7%93%D7%A9%D7%99%D7%9D%20%D7%94%D7%90%D7%97%D7%A8%D7%95%D7%A0%D7%99%D7%9D&width=1200&height=400&colorIndex=0&v=mwbxec28.yq-7cu2wow&start=20220704&end=20261111&filename=GURU_Markets_-_AZN_-_AstraZeneca-PLC_-_Year-over-year-net-earnings-per-share-change-for-the-last-twelve-months "AZN AstraZeneca Plc: צמיחת רווח למניה משנה לשנה בשנים עשר החודשים האחרונים בטווח 04.07.2022 - 11.11.2026 | 👁️GURU.Markets👁️")
AZN (AstraZeneca Corp.): פילוחים אנליטיים ודוחות לפי אינדיקטורים
This indicator measures the percentage deviation of net earnings per share for the current quarter relative to the same period last year. Positive momentum confirms growing fundamental impulse and efficient capital allocation. For AstraZeneca PLC (AZN), this growth is driven by patent monopolies and the successful navigation of regulatory barriers during drug launches. By analyzing the quarterly EPS growth rate, an investor can assess the business's resilience to market downturns.
